“…(1) SE loss in over 2 cancer types, (2) SE gain in over 2 cancer types, (3)
complex pattern: gain or loss in multiple cancer types, (4) relatively specific
loss, and (5) specific gain of SE around miRNA genes (Figure 7A). By analyzing a database for the
experimentally verified oncogenic and tumor-suppressive miRNAs (Wang et al, 2014a), miRNAs with SE gain in cancer
cells were biased toward miRNAs with oncogenic roles, and SE loss correlated
with tumor-suppressive miRNAs (Figure 7B). These changes included SE loss for miR-9 in glioblastoma cells, which is
brain-specific and decreases during glioblastoma progression (Kim et al, 2011) (Figure S7A), and SE loss for
miR-15a/16-1, a tumor suppressive miRNAs, observed in multiple cancer cells with
hematopoietic malignancies (Figure S7B).…”